- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
**Financial Highlights:** For H1 FY25, Zim Laboratories posted a total operating income of ₹1,740 Mn, a 13.6% increase from ₹1,532 Mn in H1 FY24. EBITDA grew to ₹199 Mn with an improved margin of 11.4%, up from 10.8% in the previous year. However, Profit After Tax (PAT) experienced a decline to ₹334 Mn, reflecting higher depreciation and finance costs compared to ₹433 Mn in H1 FY24.
**Strategic Initiatives and Growth Drivers:** The company filed 14 New Innovative Products (NIPs) and 6 Oral Thin Films (OTF) during H1 FY25, with plans for further submissions in Q3 and Q4. Additionally, Zim completed reaccreditation from the EU and NSF for its Dietary Supplements.
**Business Developments:** The pharma business contributed 69% (₹1,206 Mn) to revenues, while Nutra accounted for 31% (₹534 Mn). The company continues to shift focus towards developed markets, with a significant portion of revenue from innovative products.
**Market Position and Competitive Advantage:** Investing in R&D remained a priority, with ₹168 Mn allocated, emphasizing development of NIPs and OTFs. This positions Zim favorably within the competitive landscape of the pharmaceutical and nutraceutical sectors.
**Investor Implications:** The growth trajectory, supported by innovative product filings and a robust operational strategy, signals a positive outlook for Zim’s performance in the upcoming quarters, making it an attractive consideration for investors.